首页 | 本学科首页   官方微博 | 高级检索  
     

多烯紫杉醇、吉西他滨联合顺铂序贯治疗转移复发性乳腺癌临床观察
引用本文:杨泳,张家衡. 多烯紫杉醇、吉西他滨联合顺铂序贯治疗转移复发性乳腺癌临床观察[J]. 海南医学院学报, 2013, 0(11): 1558-1561
作者姓名:杨泳  张家衡
作者单位:湖北省武汉市第一医院甲乳外科,湖北武汉430022
基金项目:中国高校医学期刊临床专项资金项目(112210864)
摘    要:目的:探讨研究多烯紫杉醇、吉西他滨联合顺铂序贯治疗转移复发性乳腺癌的治疗效果和毒副作用。方法:选取我院收治的经病理检查确诊的转移复发性乳腺癌47例患者,随机分为对照组和观察组,分别给予多烯紫杉醇联合顺铂治疗和(多烯紫杉醇联合顺铂)/(吉西他滨联合顺铂)序贯治疗,比较两组治疗效果和毒副作用情况。结果:对照组和观察组有效率分别为52.4%和69.2%,疾病控制率分别为85.7%和92.3%,观察组有效率和疾病控制率高于对照组,差异无统计学意义(P〉0.05);患者化疗后主要不良反应为骨髓抑制,且两组之间比较,差异无统计学意义(P〉0.05);对两组进行为期3年的随访,对照组1年、2年和3年的生存率分别为66.7%、38.i%和19.0%,而观察组分别为84.6%、53.8%和26.9%,观察组生存率高于对照组,差异有统计学意义(P〈0.05)。结论:多烯紫杉醇、吉西他滨联合顺铂序贯治疗转移复发性乳腺癌的临床效果较好,且毒副作用未见有加重,同时提高了患者的生存率,值得在临床推广。

关 键 词:转移复发性乳腺癌  多烯紫杉醇  吉西他滨  顺铂

Clinical observation of docetaxel/gemcitabine plus cisplatin sequential chemotherapy trea- ting metastatic or relapsed breast cancer
YANG Yong,ZHANG Jia-heng. Clinical observation of docetaxel/gemcitabine plus cisplatin sequential chemotherapy trea- ting metastatic or relapsed breast cancer[J]. Journal of Hainan Medical College, 2013, 0(11): 1558-1561
Authors:YANG Yong  ZHANG Jia-heng
Affiliation:(A First Hospital of Wuhan, Hubei Province breast surgery ,430022)
Abstract:Objective= To observe the therapeutic effects and toxicity of docetaxel/gemcitabine plus cisplatin sequential chemotherapy treating metastatic or relapsed breast cancer. Methods- A total of 47 pa- tients with pathological diagnosis of metastatic or relapsed breast cancer were randomly divided into the control group and the observation group, the control group was given docetaxel plus cisplatin treatment, and the observation group was given (docetaxel plus cisplatin)/(gemcitabine plus cisplatin) sequential treatment. The treatment effects and toxicity were compared between the two groups. Results= The overall response rates of control group and observation group were 52.4% and 69. 2〈 rates were 85.7% and 92.3〈, the overall response and disease control rates were group that in control group (P〉0. 05). The major toxicity was myelosuppression difference in this aspect was observed (P〉0.05 patients in the control group was 66. 7%,38. % ). One year, two years, three and 19.0〈, and the observa 53. 8〈and 26. 9%. The survival rate of the patients in control group (P〈0. 05). Oonclusion- Docetaxe shows and it good cli improve inca the 1 efficacy on metastatic or relapse observation group was sig gemcitabine plus cisplatin th gh b e disease control er in observation ut no significant years survival rate of the tion group were 84. 6%, nificantly higher than that sequential chemotherapy breast cancer without increasing toxicity reactions, survival rate of patients, thus it is worthy of application in large scale.
Keywords:Metastatic or relapsed breast cancer  Docetaxel  Gemcitabine  Cisplatin
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号